BREAST CARE

Giving patients a better choice for fast and effective treatment

Provide patients with safe and fast in-office cryoablation therapy for fibroadenomas (benign breast tumors). Liquid nitrogen-based ProSense™ treatment rapidly and effectively destroys fibroadenomas with an advanced probe and console setup.

PROSENSETM ADVANTAGES

Clinically proven

Clinically proven

Cost effective in-office treatment

Short treatment time for fibroadenomas –
only 5-15 minutes

Touche Screen

Touch-screen console

ProSense Cryoablation System by IceCure Medical
Choice of probes

Choice of probes for
customized treatment

(small disposable
component)

Low pressure, safe, convenient and easy to use

Low pressure, safe,
convenient and easy to
use

Painless with immediate return to daily activities

Painless with immediate return to daily activities

FDA 510(k) cleared and CE marked

FDA cleared
and CE marked

HOW IT WORKS

Play Video
“When treating multiple fibroadenomas, the patient often requires multiple operations for excision and is left with multiple scars. ProSenseTM is a good alternative to regular surgery. It’s a very compact system and simple to operate. We perform the procedure under local anesthesia and there’s no pain and no adverse reactions. It’s actually very similar to core-cut biopsy and lasts less than 30 minutes. All of our patients are very satisfied with it. They’re able to go home immediately after the procedure and don’t experience complications. Over time, the destroyed fibroadenoma is completely replaced by natural fibrotic tissue.” Dr. Jan Danes MD, Professor of Radiology, Charles University in Prague

CLINICAL SUPPORT FOR PROSENSETM

The ProSense™ system is considered an optimal solution for treating fibroadenomas. Clinical studies conducted worldwide with results published in peer-reviewed medical journals demonstrate that cryoablation treatment enables shorter, simpler, and cost-effective procedures, with lower risk of infections and complications.

More information can be found in the recent American Society of Breast Surgeons (ASBS) guidelines announcement and the landmark US ICE3 clinical trial.

BreastCare Clinical Support